drugset / Trial / NCT01264575
ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty
RandomizedParallel-groupDouble-blind
Summary
This prospective randomized double-blind dose-response study is aimed to investigate the ED50 and ED95 of intrathecal bupivacaine with or without epinephrine 100 mcg for total knee replacement arthroplasty.
Timeline
- Start
- 2009-12
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 6 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 7 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 8 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 9 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 10 mg | Intrathecal |
| Subject | Bupivacaine | Other / unclassified | 11 mg | Intrathecal |
| Subject | Epinephrine | Other / unclassified | 100 ug | Intrathecal |
| Subject | Epinephrine | Other / unclassified | 200 ug | Intrathecal |
Indications
No indication recorded.